Joshua Richter, MD, director of Multiple Myeloma at the Blavatnik Family - Chelsea Medical Center at Mount Sinai, shares his perspective on the appropriate time to weigh clinical trial participation and the potential benefits. He notes that clinical trials are not always the last option once every available treatment has failed. Clinical trials offer drugs before they are approved, so patients may experience a long-lasting remission while current standard-of-care drugs are available.